Differential Effects of <i>α</i>-Glucosidase Inhibitors on Postprandial Plasma Glucose and Lipid Profile in Patients with Type 2 Diabetes Under Control with Insulin Lispro Mix 50/50

Kimura, Tomoko; Suzuki, Jinya; Ichikawa, Mai; Imagawa, Michiko; Sato, Satsuki; Fujii, Miki; Zenimaru, Yasuo; Inaba, Shin-ichi; Takahashi, Sadao; Konoshita, Tadashi; Miyamori, Isamu

doi:10.1089/dia.2012.0015

Cited by 8 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[29] investigated the additive effect of α-glucosidase inhibitors in 36 type 2 diabetic patients taking lispro mix 50/50 by three times daily injection to maintain FPG < 130 mg/dl and 2-h PPG < 180 mg/dl. Twenty patients were randomly assigned to either 0.3 mg of voglibose or 50 mg of miglitol, which was administered at breakfast every other day.…”

Section: Effects Of α-Glucosidase Inhibitorsmentioning

confidence: 99%

Mini-Special Issue paper Management of diabetic patients with hypoglycemic agents α-Glucosidase inhibitors and their use in clinical practice

Derosa¹,

Maffioli²

2012

aoms

317

106

View full text Add to dashboard Cite

Post-prandial hyperglycemia still remains a problem in the management of type 2 diabetes mellitus. Of all available anti-diabetic drugs, α-glucosidase inhibitors seem to be the most effective in reducing post-prandial hyperglycemia. We conducted a review analyzing the clinical efficacy and safety of α-glucosidase inhibitors, both alone and in combination with other anti-diabetic drugs, with respect to glycemic control, inflammation and atherosclerosis. α-Glucosidase inhibitors proved to be effective and safe both in monotherapy and as an add-on to other anti-diabetic drugs. Compared to miglitol and voglibose, acarbose seems to have some additive effects such as stabling carotid plaques, and reducing inflammation. Acarbose also proved to reverse impaired glucose tolerance to normal glucose tolerance.

show abstract

Section: Effects Of α-Glucosidase Inhibitorsmentioning

confidence: 99%

Mini-Special Issue paper Management of diabetic patients with hypoglycemic agents α-Glucosidase inhibitors and their use in clinical practice

Derosa¹,

Maffioli²

2012

aoms

317

106

View full text Add to dashboard Cite

show abstract

“…Although the mechanism of this metabolic phenotype has not been clarified, this observation may have resulted from delays in gastric emptying without adverse effects on postprandial lipid levels caused by reduced postprandial insulin secretion induced by miglitol [5]. Increased GLP-1 levels induced by miglitol after the CLT, leading to deceleration of gastric emptying, likely contributed to suppressed increases in postprandial exogenous lipid levels in the early phase [5,10,23,28]. In contrast, there are several mechanisms through which sitagliptin could have improved postprandial lipid levels.…”

Section: Conflict Of Interestmentioning

confidence: 99%

Effects of miglitol <i>versus</i> sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus

et al. 2013

View full text Add to dashboard Cite

PostPrandial hyPerglycemia and hyperlipidemia have been shown to be risk factors for atherosclerosis [1][2][3]. Potential agents to target postprandial hyperglycemia and hyperlipidemia in patients with type 2 diabetes mellitus (T2DM) include α-glucosidase inhibitors (AGIs) and dipeptidyl peptidase (DPP)-4 inhibitors. Miglitol is an AGI that improves postprandial hyperglycemia and hyperlipidemia [4] abstract. Postprandial hyperglycemia and/or hyperlipidemia can contribute to development of atherosclerosis in patients with type 2 diabetes mellitus (T2DM). The objective of this study was to compare the effects of miglitol and sitagliptin on postprandial glucose and lipid metabolism in patients with T2DM. Thirty-five patients with T2DM were randomized to 2 groups receiving miglitol (150 mg/day) or sitagliptin (50 mg/day). Serum variables related to glucose and lipid metabolism were measured before and after treatment for 10 weeks and at 0, 60, and 120 min using a cookie-loading test (CLT). After 10 weeks of treatment, miglitol (n = 16) and sitagliptin (n = 18) caused a similarly significant decrease in hemoglobin A 1c (mean: 7.6% to 7.3% versus 8.0% to 7.6%) and a significant increase in fasting insulin levels, with a greater increase observed in the miglitol group than in the sitagliptin group (p=0.03). In addition, a significant decrease in the change in glucose levels after the CLT was observed in both groups, with a greater decrease observed in the miglitol group than in the sitagliptin group (p=0.02). The miglitol group also showed a greater decrease in the change in insulin levels after the CLT than the sitagliptin group (p<0.01). The lipid and lipoprotein levels did not show any significant differences between the groups after the CLT. Our results suggested that miglitol and sitagliptin treatment resulted in similar glycemic control but that a greater decrease in postprandial glucose and insulin levels was observed with miglitol compared with sitagliptin in patients with T2DM.

show abstract

“…This short-term crossover study was performed basically as described in detail previously [22]. The 20 eligible patients were offered diabetes diet in which breakfast was made of the same materials for 6 study days.…”

Section: Methodsmentioning

confidence: 99%

“…Using our short-term crossover study design [22], the present study served to determine the efficacy of glulisine, relative to lispro, in preventing PPG excursions and effect on postprandial lipid profile.…”

Section: Introductionmentioning

confidence: 99%

Comparative effects of insulin glulisine and lispro on postprandial plasma glucose and lipid profile in Japanese patients with type 2 diabetes mellitus

et al. 2020

Self Cite

View full text Add to dashboard Cite

Objective The control of postprandial plasma glucose (PPG) excursions is critical in the prevention of diabetic complications. Controversy remains on the differences in postprandial actions of insulin glulisine and lispro. The aim of this study was to define the differences in the efficacy of these two insulin analogues on PPG. Methods The study subjects were 20 in-hospital patients with type 2 diabetes mellitus (T2DM). Plasma glucose (PG) was tightly controlled with basal insulin and insulin glulisine or lispro, and then glulisine or lispro were switched to the other insulin analog every other day for 6 study days. PG was measured before breakfast and 0.5-, 1-, and 2 h-postprandial during the study. Postprandial plasma C-peptide and lipids were analyzed in the first 2 days of the study. Postprandial increments in each parameter were compared between glulisine and lispro. Results Whereas the median value of 0.5 h-Δ-PPG was comparable in glulisine and lispro, the 1 h-Δ-PPG was significantly lower with lispro than with glulisine (41 vs 53 mg/dl, respectively, p = 0.03). Similarly, the 2 h-Δ-PPG with lispro was 10 mg/dl lower than that with glulisine (35 vs 45 mg/dl, respectively, p = 0.05). In parallel with PPG, Δ-C-peptide at 1-and 2 h-postprandial were significantly lower with lispro than glulisine (0.50 vs 0.75 ng/ml, respectively, and 0.55 vs 0.75 ng/ml, respectively). The increment in LDL-C and HDL-C was significantly lower with lispro than with glulisine at 0.5 h-postprandial. Conclusion Insulin lispro seems superior to glulisine in the control of PPG in Japanese patients with T2DM.

show abstract

Differential Effects of α-Glucosidase Inhibitors on Postprandial Plasma Glucose and Lipid Profile in Patients with Type 2 Diabetes Under Control with Insulin Lispro Mix 50/50

Abstract: Miglitol appears to have rapid action, which appears earlier than that of lispro. The combination of miglitol and Mix50 seems effective for the control of PPG and lipid profile in T2D.

Cited by 8 publications

References 29 publications

Mini-Special Issue paper Management of diabetic patients with hypoglycemic agents α-Glucosidase inhibitors and their use in clinical practice

Mini-Special Issue paper Management of diabetic patients with hypoglycemic agents α-Glucosidase inhibitors and their use in clinical practice

Effects of miglitol <i>versus</i> sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus

Comparative effects of insulin glulisine and lispro on postprandial plasma glucose and lipid profile in Japanese patients with type 2 diabetes mellitus

Contact Info

Product

Resources

About